Detalles de la búsqueda
1.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Clin Infect Dis
; 2024 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38305378
2.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood
; 129(19): 2612-2615, 2017 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28373262
3.
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
Eur J Haematol
; 2018 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30030853
4.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 369(1): 32-42, 2013 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-23782158
5.
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
Br J Clin Pharmacol
; 81(2): 235-45, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26382728
6.
Absorption, metabolism, and excretion of oral ¹4C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Drug Metab Dispos
; 43(2): 289-97, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25488930
7.
Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine.
Br J Clin Pharmacol
; 69(5): 498-507, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20573085
8.
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Hematology
; 25(1): 112-117, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32131714
9.
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Pharmacol Res Perspect
; 8(5): e00649, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32945596
10.
Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.
J Pharmacol Exp Ther
; 330(3): 911-21, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19502531
11.
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
Cancer Chemother Pharmacol
; 81(2): 423, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29214363
12.
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
Cancer Chemother Pharmacol
; 82(2): 299-308, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29882017
13.
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Leuk Lymphoma
; 59(12): 2888-2895, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846137
14.
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Mol Cancer Ther
; 5(7): 1774-82, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16891463
15.
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
Cancer Chemother Pharmacol
; 80(6): 1227-1237, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29080970
16.
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment.
Leuk Lymphoma
; 58(1): 185-194, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27267254
17.
Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.
Toxicol In Vitro
; 20(2): 154-62, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16321501
18.
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Mol Cancer Ther
; 15(12): 2835-2844, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27678331
19.
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Clin Cancer Res
; 9(15): 5729-34, 2003 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14654558
20.
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Clin Cancer Res
; 9(1): 327-37, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12538485